EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Matrifibrocytes Redefine Cardiac Fibrosis: From Terminal Differentiation to Translational Modulation

Zhentao Zhang, Hua Zhu

Journal of Cellular and Molecular Medicine · 2026-05 · 30 (10)

DOI: 10.1111/jcmm.71174 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 13.05.2026. Verfasst von Zhentao Zhang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Cell Differentiation, Myofibroblasts, Myocardium, Fibroblasts. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NIA NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiac fibrosis is increasingly recognized as a dynamic program that resolves into a terminal fibroblast fate, the matrifibrocyte, rather than a persistent myofibroblast state. Lineage‐tracing and single‐cell studies reveal that matrifibrocytes arise from activated myofibroblasts during late scar maturation, lose α ‐SMA and proliferative capacity, and adopt a cartilage‐like ECM program (e.g., Comp , Chad , Thbs4 , Sfrp2 ). Functionally, they stabilize collagen architecture, sustain tensile strength and shape an immune‐quiescent, angiogenesis‐restrained microenvironment. We synthesize evidence suggesting that TGF‐ β restraint (e.g., Smad7 ), matrix mechanics (YAP/TAZ), Wnt attenuation ( Sfrp2 ), Comp–Notch3 feedback, and Thbs4–Atf6α ER‐stress adaptation converge to establish or maintain this terminal state. We further summarize disease contexts beyond infarction, including pressure overload and valvular disease, where matrifibrocyte‐like programs emerge and may contribute to chronic stiffening. Finally, we outline translational strategies that either accelerate matrifibrocyte maturation to secure scars after acute injury or reset terminal states via pharmacology or direct reprogramming to regress fibrosis. Framing matrifibrocytes as an adjustable endpoint reconciles structural integrity with functional recovery and highlights actionable checkpoints for precision anti‐fibrotic therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell DifferentiationMyofibroblastsMyocardiumFibroblastsHumansFibrosisAnimalsExtracellular Matrix

Stichwörter der Autor:innen

cardiac fibroblastfibrosismatrifibrocytemyofibroblastscar maturation

Autor:innen und Institutionen

  • Department of Surgery, Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Förderung

  • NIAMS NIH HHS
  • NIA NIH HHS
  • NIH HHS
  • American Heart Association
  • NHLBI NIH HHS
  • National Institutes of Health

Zitieren

APA

Zhang, Z., & Zhu, H. (2026). Matrifibrocytes Redefine Cardiac Fibrosis: From Terminal Differentiation to Translational Modulation. Journal of Cellular and Molecular Medicine, 30(10). https://doi.org/10.1111/jcmm.71174

Vancouver

Zhang Z, Zhu H. Matrifibrocytes Redefine Cardiac Fibrosis: From Terminal Differentiation to Translational Modulation. Journal of Cellular and Molecular Medicine. 2026;30(10). doi:10.1111/jcmm.71174

BibTeX
@article{Zhang2026,
  author = {Zhang, Zhentao and Zhu, Hua},
  title = {Matrifibrocytes Redefine Cardiac Fibrosis: From Terminal Differentiation to Translational Modulation},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  volume = {30},
  number = {10},
  doi = {10.1111/jcmm.71174}
}
Kostenlos starten →